Author
Centre Hospitalier de l’Université de Montréal
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
4 papers
Recent·Most cited
Mallory I. Frederick, Nicolas Pouderous, Kenan Aloss, Qi Yang, Gerardo Ferbeyre, Saima Noor Hassan
This study shows that combining PARPi with ribosome biogenesis inhibitors sensitizes PARPi-resistant triple-negative breast cancer cells and identifies ribosome biogenesis as a therapeutic target.
bioRxiv · Oct 9, 2026 · PreprintCancer Biology
Owen F.J. Hovey, Alyssa Wu, Tingting Wu, Jenica H. Kakadia, Mallory I. Frederick, Ilka U. Heinemann, Shawn Li
This study shows that inhibiting LIN28A with LIN28i-1632 enhances imatinib sensitivity in imatinib-resistant CML cells by reducing BCR-ABL abundance and disrupting the AKT survival pathway.
bioRxiv · Apr 29, 2026 · PreprintCancer Biology
Owen F.J. Hovey, Mallory I. Frederick, Quan M. Quach, Jenica H. Kakadia, Alyssa Wu, Kyle Yang, Tingting Wu, Xiang Ruan, Tomonori Kaneko, Courtney Voss, Ilka U. Heinemann, Shawn S.‐C. Li
This study identifies LIN28A as a mediator of imatinib resistance in CML by reprogramming the kinome and phosphoproteome, with potential therapeutic implications for overcoming resistance.
Molecular & Cellular Proteomics · Jan 20, 2026Peer-reviewedCancer Biology
Mallory I. Frederick, Elicia Fyle, Anna Clouvel, Djihane Abdesselam, Saima Noor Hassan
This study identifies FEN1 as a target to enhance PARP inhibitor efficacy in PARPi-resistant triple-negative breast cancer cell lines and organoids.
Translational Oncology · Mar 6, 2025Peer-reviewedCancer Biology